Open AccessCyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up
Author(s) -
Jule F Vasquez,
Rossana Ruiz,
Karina Mayra Aliaga Llerena,
Fernando Valencia,
Marco Villena,
Shirley Quintana,
Tatiana Vidaurre,
Luís Casanova
Publication year - 2021
Publication title -
jco global oncology
Language(s) - English
Resource type - Journals
ISSN - 2687-8941
DOI - 10.1200/go.20.00665
Subject(s) - medicine , thalidomide , neutropenia , dexamethasone , cyclophosphamide , multiple myeloma , adverse effect , surgery , chemotherapy , gastroenterology
Major progress has occurred in multiple myeloma (MM) treatment in recent years, but this is not seen in low- and middle-income countries.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom